← TALPHERA, INC. (TLPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TALPHERA, INC. (TLPH)
Pharmaceutical Preparations · market cap $61M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
10
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Talphera, Inc. (TLPH) is a micro-cap pharmaceutical company focused on sublingual sufentanil formulations for acute and post-operative pain, with a lead asset (sufentanil sublingual 30 mcg tablet) in Phase 3 and an estimated NDA filing in early 2027. The company carries a $73M market cap but holds only $3.8M in cash — roughly 3.4 months of runway — creating acute financing risk ahead of any regulatory milestone.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-01 (est.)NDA Filingimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| sufentanil sublingual 30 mcg tablet | Phase 3 | Moderate-to-severe Acute Pain |
| Oral sufentanil | Phase 2 | Major Upper or Lower Abdominal Surgery |
| Sufentanil NanoTab PCA System/15 mcg | Phase 3 | Pain, Postoperative |
| Sufentanil NanoTab 20 mcg | Phase 2 | Acute Pain |
| sufentanil sublingual tablet 30 mcg | Phase 3 | Acute Moderate-to-severe Pain |
| Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) | Phase 2 | Sedation |
| Zalviso™ 15 mcg | Phase 3 | Moderate-to-severe Acute Pain |
| Sufentanil Tablet 30 mcg | Phase 3 | Post-Operative Pain |
| Sufentanil NanoTab | Phase 2 | Post Operative Pain |
| morphine IV PCA | Phase 3 | Post-Operative Pain |
Price & technical context
3-month
+4.7%
6-month
+43.6%
12-month
+25.8%
52-wk range
$0.72–$1.47
vs 50-day MA
-10.0%
vs 200-day MA
+10.3%
Realized vol
77.4%
Max drawdown
-66.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TLPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.